C. Lebreton

Pembrolizumab and Chemotherapy in Cervical Cancer: A New Standard of Care?

I. Ray-Coquard, B. Méry, O. Saux, 2022, Oncology & Haematology.

Update on new treatments for rare ovarian tumours

I. Ray-Coquard, Stanislas Quesada, C. Lebreton, 2022, Current opinion in obstetrics & gynecology.

Pelvic insufficiency fractures after intensity modulated radiation therapy combined with chemotherapy for cervix carcinoma: Incidence and impact of bone mineral density

F. Guyon, W. Bouleftour, A. Petit, 2023, Clinical and translational radiation oncology.

An arterio-venous malformation related to a uterine scar defect, an unusual association.

X. Deffieux, A. Vivanti, S. Maitre, 2020, Journal of Gynecology Obstetrics and Human Reproduction.

Incidence and prognostic factors of clinically meaningful toxicities of kinase inhibitors in older patients with cancer: The PreToxE study.

A. Italiano, C. Bellera, E. Paillaud, 2020, Journal of geriatric oncology.

[Tertiary lymphoid structures in cancer: From biology to therapeutic guides].

A. Italiano, C. Caux, C. Caux, 2023, Bulletin du cancer.

Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial

I. Vergote, J. Sehouli, F. Joly, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Treatments for rare ovarian tumors: What's new?]

F. Guyon, O. Trédan, N. Chopin, 2023, Bulletin du cancer.